DUSA offers a high conviction, value-focused approach with a concentrated portfolio. Learn more about DUSA ETF and my ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, is on track to become cash flow positive by the end of this year, following a strong Q2 ...

Shares of Viatris Inc. VTRS advanced 1.41% to $9.37 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to 6,358.91 and ...

Attorney General Alan Wilson announced approximately $720 million nationwide in settlements with eight drug makers that ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...